GlassScriptPhysician profile
Hadeel E Ali Hamdan
NPI 1407501752
$2,066.82
in general payments reported to CMS, 2019-2025
25 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $464 · 2024: $692 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $231.98 | 2023-2025 | Airsupra, Breztri |
| Pfizer INC. | $146.56 | 2023-2025 | |
| Glaxosmithkline, LLC. | $145.20 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $141.74 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $129.56 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Penumbra, INC. | $113.59 | 2023 | Indigo System |
| Intuity Medical INC | $90.88 | 2022 | |
| Abbvie INC. | $86.57 | 2023-2024 | |
| Inari Medical, INC. | $82.08 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.26 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $57.78 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $47.95 | 2023-2024 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
| Boston Scientific Corporation | $44.83 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Inogen, INC. | $33.68 | 2024-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $26.45 | 2024 | Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $25.18 | 2022 | |
| Noven Therapeutics, LLC | $24.95 | 2025 | Xelstrym |
| Astellas Pharma US INC | $22.58 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $19.78 | 2022 | |
| Neuronetics, INC. | $18.26 | 2025 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $16.26 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.39 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $14.22 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadeel Ali Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.